Financial News

Gilead’s stock has fallen 21% since April 30, underscoring investor questions about remdesivir’s potential

In the four months since Gilead Sciences Inc. first received emergency authorization for its experimental COVID-19 drug remdesivir, its stock has done the opposite of what you would expect — it has dropped 21%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback